Cemiplimab Clinical Trials
74 recruitingDrug
Phase 254Phase 124Phase 36
Showing 1–20 of 74 trials
Recruiting
Phase 2
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled3 locationsNCT06980038
Recruiting
Phase 3
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled196 locationsNCT06568172
Recruiting
Phase 2
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Sinonasal Squamous Cell CarcinomaStage III Sinonasal Cancer AJCC v8Stage IVA Sinonasal Cancer AJCC v8+1 more
National Cancer Institute (NCI)108 enrolled1 locationNCT07281417
Recruiting
Phase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled28 locationsNCT07195734
Recruiting
Phase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more
National Cancer Institute (NCI)48 enrolled55 locationsNCT06900595
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled50 locationsNCT06787612
Recruiting
Phase 1Phase 2
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Advanced Solid Tumors
Regeneron Pharmaceuticals933 enrolled57 locationsNCT04626635
Recruiting
Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (CSCC)
Regeneron Pharmaceuticals369 enrolled49 locationsNCT06585410
Recruiting
Phase 2
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Advanced Renal Cell Carcinoma (aRCC)
Brian Rini120 enrolled1 locationNCT07188896
Recruiting
Phase 3
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
ETOP IBCSG Partners Foundation390 enrolled34 locationsNCT06931717
Recruiting
Phase 2
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)
Gustave Roussy, Cancer Campus, Grand Paris162 enrolled6 locationsNCT07001618
Recruiting
Phase 2
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Metastatic NSCLC - Non-Small Cell Lung Cancer
Swiss Cancer Institute156 enrolled17 locationsNCT07020065
Recruiting
Phase 3
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Brain Tumor
InSightec30 enrolled9 locationsNCT05317858
Recruiting
Phase 1
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Head and Neck CancerHead and Neck Squamous Cell CarcinomaHNSCC+3 more
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT04722523
Recruiting
Phase 2
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Advanced Melanoma
Memorial Sloan Kettering Cancer Center88 enrolled11 locationsNCT06594991
Recruiting
Phase 2
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
Solid Tumors
M.D. Anderson Cancer Center40 enrolled1 locationNCT06651593
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic127 enrolled2 locationsNCT03017820
Recruiting
Phase 2
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled2 locationsNCT06769698
Recruiting
Phase 2
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Basal Cell CarcinomaLocally Advanced Basal Cell Carcinoma
Thomas Jefferson University70 enrolled3 locationsNCT05929664
Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319